Dexmedetomidine inhibits inflammation and angiogenesis and alleviates esophageal cancer progression through ITGA6/PI3K/AKT pathway: Dexmedetomidine inhibits esophageal cancer progression. Indian Journal of Experimental Biology (IJEB), [S. l.], v. 64, n. 01, p. 15–32, 2026. DOI: 10.56042/ijeb.v64i01.22881. Disponível em: https://or.niscpr.res.in/index.php/IJEB/article/view/22881. Acesso em: 13 may. 2026.